IGF2 DMR0 methylation, loss of imprinting, and patient prognosis in esophageal squamous cell carcinoma

Annals of Surgical Oncology

Volumn 21, Issue 4, 2014, Pages 1166-1174

  Murata, Asuka ^a   Baba, Yoshifumi ^a   Watanabe, Masayuki ^a   Shigaki, Hironobu ^a   Miyake, Keisuke ^a   Ishimoto, Takatsugu ^a   Iwatsuki, Masaaki ^a   Iwagami, Shiro ^a   Yoshida, Naoya ^a   Oki, Eiji ^b   Morita, Masaru ^b   Nakao, Mitsuyoshi ^c   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN B;

ADULT; AGED; ARTICLE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR IMPRINTING; PYROSEQUENCING;

AGED; CARCINOMA, SQUAMOUS CELL; DNA METHYLATION; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC IMPRINTING; HUMANS; IMMUNOENZYME TECHNIQUES; INSULIN-LIKE GROWTH FACTOR II; LYMPHATIC METASTASIS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL RATE;

EID: 84896093645     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3414-7     Document Type: Article

References (47)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241-52. (Pubitemid 37485141)
2. Gertler R, Stein HJ, Langer R, et al. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system. Ann Surg. 2011;253:689-98.
3. Rizk NP, Ishwaran H, Rice TW, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251:46-50.
4. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062-7.
5. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and metaanalysis. Gut. 2004;53:925-30. (Pubitemid 38824146)
6. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamouscell cancer of the esophagus. N Engl J Med. 1997;337:161-7. (Pubitemid 27306287)
7. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 2003;299:1753-5. (Pubitemid 36337205)
8. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330-7.
9. Ho L, Stojanovski A, Whetstone H, et al. Gli2 and p53 cooperate to regulate IGFBP-3-mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. Cancer Cell. 2009;16:126-36.
10. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, Feinberg AP. Relaxation of imprinted genes in human cancer. Nature. 1993;362:747-9. (Pubitemid 23125977)
11. Ogawa O, Eccles MR, Szeto J, et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature. 1993;362:749-51. (Pubitemid 23125978)
12. Morison IM, Becroft DM, Taniguchi T, Woods CG, Reeve AE. Somatic overgrowth associated with overexpression of insulinlike growth factor II. Nat Med. 1996;2:311-6. (Pubitemid 26080651)
13. Timp W, Levchenko A, Feinberg AP. A new link between epigenetic progenitor lesions in cancer and the dynamics of signal transduction. Cell Cycle. 2009;8:383-90.
14. Harper J, Burns JL, Foulstone EJ, Pignatelli M, Zaina S, Hassan AB. Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting. Cancer Res. 2006;66:1940-8.
15. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science. 2005;307:1976-8. (Pubitemid 40404709)
16. Kaneda A, Wang CJ, Cheong R, et al. Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc Natl Acad Sci USA. 2007;104:20926-31.
17. Baba Y, NoshoK, Shima K, et al.Hypomethylation of the IGF2DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastroenterology. 2010;139:1855-64.
18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180-4. (Pubitemid 41258223)
19. Ogino S, Nosho K, Kirkner GJ, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst. 2008;100:1734-8.
20. Baba Y, Huttenhower C, Nosho K, et al. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer. 2010;9:125.
21. Zhao R, DeCoteau JF, Geyer CR, Gao M, Cui H, Casson AG. Loss of imprinting of the insulin-like growth factor II (IGF2) gene in esophageal normal and adenocarcinoma tissues. Carcinogenesis. 2009;30:2117-22.
22. Chava S, Mohan V, Shetty PJ, et al. Immunohistochemical evaluation of p53, FHIT, and IGF2 gene expression in esophageal cancer. Dis Esophagus. 2012;25:81-7.
23. Fitzgerald RC. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut. 2006;55:1810-20.
24. Baba Y, Watanabe M, Shigaki H, et al. Negative lymph-node count is associated with survival in patients with resected esophageal squamous cell carcinoma. Surgery. 2013;153:234-41.
25. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res. 2002;62:6442-6. (Pubitemid 35364103)
26. Cheng YW, Idrees K, Shattock R, et al. Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer. Int J Cancer. 2010;127:568-77.
27. Ito Y, Koessler T, Ibrahim AE, et al. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum Mol Genet. 2008;17:2633-43.
28. Ohta M, Sugimoto T, Seto M, et al. Genetic alterations in colorectal cancers with demethylation of insulin-like growth factor II. Hum Pathol. 2008;39:1301-8.
29. Sasaki J, Konishi F, Kawamura YJ, Kai T, Takata O, Tsukamoto T. Clinicopathological characteristics of colorectal cancers with loss of imprinting of insulin-like growth factor 2. Int J Cancer. 2006;119:80-3.
30. Nakagawa H, Chadwick RB, Peltomaki P, Plass C, Nakamura Y, de La Chapelle A. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci USA. 2001;98:591-6. (Pubitemid 32105087)
31. Nishihara S, Hayashida T, Mitsuya K, et al. Multipoint imprinting analysis in sporadic colorectal cancers with and without microsatellite instability. Int J Oncol. 2000;17:317-22.
32. Xu W, Fan H, He X, Zhang J, Xie W. LOI of IGF2 is associated with esophageal cancer and linked to methylation status of IGF2 DMR. J Exp Clin Cancer Res. 2006;25:543-7. (Pubitemid 46166769)
33. Mori M, Inoue H, Shiraishi T, et al. Relaxation of insulin-like growth factor 2 gene imprinting in esophageal cancer. Int J Cancer. 1996;68:441-6. (Pubitemid 26414497)
34. Wu MS, Wang HP, Lin CC, et al. Loss of imprinting and overexpression of IGF2 gene in gastric adenocarcinoma. Cancer Lett. 1997;120:9-14.
35. Lu Y, Lu P, Zhu Z, Xu H, Zhu X. Loss of imprinting of insulinlike growth factor 2 is associated with increased risk of lymph node metastasis and gastric corpus cancer. J Exp Clin Cancer Res. 2009;28:125.
36. Zuo QS, Yan R, Feng DX, et al. Loss of imprinting and abnormal expression of the insulin-like growth factor 2 gene in gastric cancer. Mol Carcinog. 2011;50:390-6.
37. Murrell A, Ito Y, Verde G, et al. Distinct methylation changes at the IGF2-H19 locus in congenital growth disorders and cancer. PLoS One. 2008;3:e1849.
38. Ishii T, Murakami J, Notohara K, et al. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut. 2007;56:13-9.
39. Paterson AL, Shannon NB, Lao-Sirieix P, et al. A systematic approach to therapeutic target selection in oesophago-gastric cancer. Gut. 2013;62:1415-24.
40. Maley CC. Open questions in oesophageal adenocarcinogenesis. Gut. 2007;56:897-8. (Pubitemid 46999068)
41. Wong DJ, Paulson TG, Prevo LJ, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res. 2001;61:8284-9. (Pubitemid 33091623)
42. Taby R, Issa JP. Cancer epigenetics. CA Cancer J Clin. 2010;60:376-92.
43. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17:330-9.
44. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4:143-53. (Pubitemid 38198742)
45. Peng DF, Razvi M, Chen H, et al. DNA hypermethylation regulates the expression of members of the Mu-class glutathione Stransferases and glutathione peroxidases in Barrett's adenocarcinoma. Gut. 2009;58:5-15.
46. Shen H, Laird PW. In epigenetic therapy, less is more. Cell Stem Cell. 2012;10:353-4.
47. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5:37-50.